Aytu BioPharma
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Aytu BioPharma's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 25% to $81,002,000. The net income raised on -$15,844,000 and profit margin reached -20%. Total operating expenses were $60,570,000.
Profit Margin
| 2015 | 261.78K | -7.72M | -2950.32% |
|---|---|---|---|
| 2016 | 2.56M | -28.18M | -1099.73% |
| 2017 | 3.22M | -22.50M | -698.67% |
| 2018 | 3.66M | -10.18M | -278.36% |
| 2019 | 7.32M | -47.16M | -644.33% |
| 2020 | 27.63M | -13.62M | -49.29% |
| 2021 | 65.63M | -58.28M | -88.81% |
| 2022 | 96.66M | -110.17M | -113.97% |
| 2023 | 107.39M | -17.05M | -15.88% |
| 2024 | 81.00M | -15.84M | -19.56% |
AYTU Income Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 81.00M | 107.39M | 96.66M | 65.63M | 27.63M | 7.32M | 3.66M | 3.22M | 2.56M | 261.78K |
Cost of revenue | 26.41M | 40.76M | 44.38M | 36.43M | 7.55M | 2.20M | 2.05M | 1.41M | 957.07K | 88.10K |
Gross profit | 54.58M | 66.63M | 52.28M | 29.2M | 20.07M | 5.11M | 1.60M | 1.80M | 1.60M | 173.67K |
Operating exp. | ||||||||||
Research and development | 2.79M | 4.09M | 14.43M | 5.62M | 1.72M | 589.07K | 167.59K | 1.34M | 6.31M | 3.42M |
Selling and marketing | 26.95M | 41.44M | 38.71M | 30.30M | 11.40M | 0 | 0 | -242 | 0 | 0 |
Total operating expenses | 60.57M | 78.96M | 88.38M | 67.44M | 41.01M | 21.96M | 19.45M | 20.66M | 15.80M | 7.80M |
Operating income | -5.25M | -17.06M | 37.21M | -38.24M | -20.93M | -16.84M | -19.70M | -20.12M | -21.70M | -7.63M |
Other income (expenses), net | -8.82M | 14K | -147.49M | -19.79M | 7.51M | -10.28M | 8.40M | -2.38M | -8.48M | -114.99K |
Income before tax | -14.07M | -17.05M | -110.28M | -58.03M | -13.62M | -27.13M | -10.18M | -22.50M | -28.18M | -7.74M |
Income tax expense | 1.76M | -57K | -110K | 259K | -9.92M | 20.03M | -2.12M | 1.11M | 8.48M | -23.91K |
Net income | -15.84M | -17.05M | -110.17M | -58.28M | -13.62M | -47.16M | -10.18M | -22.50M | -28.18M | -7.72M |
Earnings per share | ||||||||||
Basic EPS | -2.86 | -5.11 | -74.95 | -69.61 | -60.2 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K |
Diluted EPS | -2.86 | -5.11 | -74.95 | -69.61 | -60.2 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |